VerninoSBourneKMStilesLE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting—Part 1. Auton Neurosci. 2021;235:102828.
3.
FreemanRWielingWAxelrodFB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
4.
ZaqqaMMassumiA. Neurally mediated syncope. Tex Heart Inst J. 2000;27(3):268-272.
5.
MalfaitFFrancomanoCByersP, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.
6.
KimCHLeungAHuhYH, et al. Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine beta-hydroxylase. J Biol Chem. 2011;286:9196-9204.
7.
ArnoldACGarlandEMCeledonioJE, et al. Hyperinsulinemia and insulin resistance in dopamine β-hydroxylase deficiency. J Clin Endocrinol Metab. 2017;102:10-14.
8.
RuziehMDasaOPacentaAKarabinBGrubbB. Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am J Ther. 2017;24(2):e157-e161.
9.
GarlandEMBlackBKHarrisPARobertsonD. Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2007;293(1):H684-H690.
10.
VincentSRobertsonD. The broader view: catecholamine abnormalities. Clin Auton Res. 2002;12(suppl 1):I44-149.
